



## Javelin Pharmaceuticals, Inc. Tops Up Balance Sheet Through Registered Direct Offering

CAMBRIDGE, Mass., Oct 30, 2009 (BUSINESS WIRE) -- Javelin Pharmaceuticals, Inc. (NYSEAmex: JAV), a leading developer and marketer of specialty pharmaceutical products for pain management, today received commitments from a single institutional investor, to purchase up to 3,186,700 shares of its common stock for estimated gross proceeds of approximately \$3.9 million.

Copies of the final prospectus supplement and accompanying base prospectus relating to this offering may be obtained at the Securities and Exchange Commission's web site at <http://www.sec.gov>, or from Javelin Pharmaceuticals, Inc., 125 CambridgePark Drive, Cambridge, MA 02140 Attention: General Counsel.

A shelf registration statement relating to the securities being offered has been filed with the Securities and Exchange Commission and has become effective. This communication shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.

### About Javelin

With corporate headquarters in Cambridge, MA, Javelin applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs to target unmet and underserved medical needs in the acute pain management market. The Company has one marketed drug in the UK and three drug candidates in US Phase 3 clinical development. For additional information about Javelin, please visit the Company's website at <http://www.javelinpharmaceuticals.com>.

### Forward Looking Statement

This news release contains forward-looking statements. Such statements are valid only as of today, and we disclaim any obligation to update this information. These statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made, including today's initial study results. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA review process and other governmental regulation, our ability to obtain working capital, our ability to successfully develop and commercialize drug candidates, and competition from other pharmaceutical companies

JAV-F

SOURCE: Javelin Pharmaceuticals, Inc.

Javelin Pharmaceuticals, Inc.  
Stephen J. Tulipano, CPA, 617-349-4500  
Chief Financial Officer  
[stulipano@javelinpharma.com](mailto:stulipano@javelinpharma.com)

or

Javelin Pharmaceuticals, Inc.  
Investor Relations & Media  
Rick Pierce, 617-349-4500  
VP, Investor Relations  
[rpierce@javelinpharma.com](mailto:rpierce@javelinpharma.com)

Copyright Business Wire 2009